<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sleep-disordered breathing in patients chronically using opioids</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sleep-disordered breathing in patients chronically using opioids</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Sleep-disordered breathing in patients chronically using opioids</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shirin Shafazand, MD, MS, FRCP(C), FCCP, FAASM</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">M Safwan Badr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 17, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H14082102"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Prescription opioid use for chronic non-cancer pain has increased dramatically over the past two decades. Although the prevalence and impact of respiratory depression due to opioids were at one time de-emphasized [<a href="#rid1">1</a>], there is now a growing appreciation for the adverse effects of chronic opioid use, including increased mortality [<a href="#rid2">2</a>]. Emerging data also suggest that there is an increased incidence of sleep-disordered breathing (SDB) with chronic opioid use, with possible negative consequences.</p><p>Given the relatively high prevalence of both obstructive sleep apnea (OSA) and chronic pain in the general population, clinicians are likely to encounter patients with pre-existing or undiagnosed OSA who are using opioids for chronic pain. Awareness of the sleep and respiratory effects of chronic opioid use is essential in the safe management of these patients [<a href="#rid3">3</a>].</p><p>The effects of chronic opioid use on sleep architecture and respiration during sleep, and the diagnosis and treatment of opioid-associated SDB are reviewed here. Acute opioid use and its impact on patients with OSA in the perioperative setting are discussed separately. The respiratory and other effects of acute opioid intoxication are also reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/13516.html" rel="external">"Surgical risk and the preoperative evaluation and management of adults with obstructive sleep apnea"</a> and  <a class="medical medical_review" href="/z/d/html/13517.html" rel="external">"Intraoperative management of adults with obstructive sleep apnea"</a> and  <a class="medical medical_review" href="/z/d/html/13518.html" rel="external">"Postoperative management of adults with obstructive sleep apnea"</a> and  <a class="medical medical_review" href="/z/d/html/300.html" rel="external">"Acute opioid intoxication in adults"</a>.)</p><p class="headingAnchor" id="H1326602816"><span class="h1">EFFECTS OF OPIOIDS ON SLEEP AND RESPIRATION</span></p><p class="headingAnchor" id="H14082108"><span class="h2">Sleep architecture</span><span class="headingEndMark"> — </span>Limited data suggest that opioids are disruptive to sleep architecture, despite their sedative effects. Acute opioid use causes more frequent shifts in sleep states, increased arousals from sleep, an increase in non-rapid eye movement (NREM) stage 2 sleep, and reductions in total sleep time, amount of slow wave (stage N3) sleep, and rapid eye movement (REM) sleep [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/7710.html" rel="external">"Stages and architecture of normal sleep"</a>.)</p><p>With chronic opioid use, there is a tendency for the percent time spent in REM and slow wave sleep to normalize, but there is an increase in daytime sleepiness and reported fatigue [<a href="#rid5">5</a>]. Withdrawal from chronic opioid use may lead to insomnia, increased arousals from sleep, and rebound in REM and slow wave sleep.</p><p class="headingAnchor" id="H14082114"><span class="h2">Respiratory control</span><span class="headingEndMark"> — </span>The control of breathing during wakefulness is a complex interaction between central respiratory centers, central and peripheral chemoreceptors, and lung mechanical/stretch receptors, with input from voluntary behaviors and environmental stimuli. (See  <a class="medical medical_review" href="/z/d/html/5112.html" rel="external">"Control of ventilation"</a>.)</p><p>During both wakefulness and REM sleep, control of breathing is primarily determined by the central respiratory centers and secondarily by metabolic controls of breathing, involving inputs from peripheral and central chemoreceptors that detect changes in carbon dioxide, oxygen levels, or pH. During NREM sleep, metabolic controls play an important role in respiration. </p><p>Variations in respiration occur during the course of normal sleep, many of which may be vulnerable to the effects of opioids.</p><p class="bulletIndent1"><span class="glyph">●</span>During NREM sleep, breathing usually remains regular, with a small decrease in total minute ventilation related to a decrease in respiratory rate and a small decrease in tidal volume [<a href="#rid6">6</a>]. Respiratory drive in response to hypercapnia and activity in the accessory muscles of respiration are decreased, and activity in upper airway muscles is often reduced. This may increase upper airway resistance in normal individuals [<a href="#rid7">7</a>], but is thought to play a more important role in those predisposed to sleep-disordered breathing (SDB). (See  <a class="medical medical_review" href="/z/d/html/7712.html" rel="external">"Pathophysiology of upper airway obstruction in obstructive sleep apnea in adults", section on 'Determinants of upper airway patency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>During REM sleep, breathing is irregular, with breath-to-breath variations in tidal volume. There may be significant hypercapnia seen in some individuals during REM, and an increase in upper airway resistance with diminished upper airway dilator muscle tone may occur. Additionally, minute ventilation depends largely on the diaphragm alone, as the accessory muscles of respiration become partially atonic during REM sleep, whereas the diaphragm is spared.</p><p></p><p>Acute and chronic administration of opioids may affect many of these processes during both wakefulness and sleep. Opioids decrease awake central respiratory drive, with a resultant decrease in tidal volume, respiratory rate, and minute ventilation. The central and peripheral responses to hypoxic and hypercapnic stimuli are diminished during wakefulness. Acutely, opioid administration has also been associated with increased upper airway resistance and rigidity of accessory muscles of respiration [<a href="#rid6">6,8</a>].</p><p>During sleep, the combination of physiologic changes in respiration and chronic opioid use can lead to significant alterations and irregularity in breathing. The exact mechanism of central apneas associated with chronic opioid use is unknown but may be due in part to the respiratory instability that is caused by reduced hypercarbic ventilatory drive and increased hypoxemic ventilatory drive [<a href="#rid9">9,10</a>]. </p><p>There are fewer data on the long-term impact of chronic opioid use on respiratory and ventilatory parameters during wakefulness, and more research is needed to determine whether any of the changes are persistent or clinically significant. Hypoxemia and hypercarbia during wakefulness have been observed in some chronic opioid users.</p><p class="headingAnchor" id="H14082120"><span class="h1">PREVALENCE</span><span class="headingEndMark"> — </span>Sleep-disordered breathing (SDB) is an umbrella term used to describe varying combinations of hypoventilation, obstructive apneas, central apneas, mixed apneas, and irregular breathing during sleep. (See  <a class="medical medical_review" href="/z/d/html/99553.html" rel="external">"Polysomnography in the evaluation of sleep-disordered breathing in adults"</a>.)</p><p>Central sleep apnea (CSA) is the most common form of SDB in opioid users, although mixed patterns may occur and the quality of the data is limited. Most studies are small and consist of referral populations. In two studies that reported on the relative distribution of central versus obstructive apneas among chronic opioid users, CSA was four to six times more common than obstructive sleep apnea (60 versus 10 percent and 30 versus 8 percent) [<a href="#rid11">11,12</a>].</p><p>A systematic review on CSA and chronic opioid use identified eight studies comprising 560 patients [<a href="#rid13">13</a>]. In this review, the overall prevalence of SDB (defined as an apnea-hypopnea index [AHI] ≥5) ranged from 42 to 85 percent, with the highest estimate obtained in a cohort of patients specifically referred for evaluation of sleep apnea. The mean prevalence of CSA was 24 percent. In studies that reported the central sleep apnea index (CAI), the mean CAI ranged from 5 to 13 per hour [<a href="#rid14">14</a>].</p><p>In a study of 50 patients on long-term <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> maintenance therapy and matched controls, the mean AHI was significantly higher in patients on methadone (44 versus 30 per hour), and this was primarily due to an increase in central apneas (13 versus 2 per hour) [<a href="#rid15">15</a>]. The severity of central apneas correlated in part with methadone levels in blood, awake arterial carbon dioxide tension (PaCO<sub>2</sub>) levels, concomitant antidepressant use, reduced ventilatory response to hypercapnia, increased ventilator response to hypoxemia, and widened awake alveolar-arterial oxygen pressure gradients. </p><p class="headingAnchor" id="H1326603284"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>Risk factors for sleep-disordered breathing (SDB) in patients chronically using opioids are not well established but appear to be largely distinct from classical risk factors for obstructive sleep apnea (OSA; eg, advancing age, obesity, male sex). </p><p>The most consistently identified risk factors are low to low-normal body mass index and daily dose of opioid [<a href="#rid13">13,16,17</a>]. In particular, daily doses greater than 200 mg <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> dose equivalents appear to confer higher risk [<a href="#rid16">16</a>]. SDB has been observed in stable patients enrolled in <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> maintenance programs as well as those receiving high potency opioids for management of cancer-related pain [<a href="#rid8">8,15</a>]. The type of opioid used appears to be less important than the morphine dose equivalent in conferring SDB risk. </p><p>Other risk factors identified in some but not all studies include concomitant antidepressant use and concomitant benzodiazepine use [<a href="#rid14">14,15</a>]. The concomitant use of gabapentinoids (<a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>) and opioids has been associated with increased odds of opioid-related deaths [<a href="#rid18">18</a>]. While the underlying etiology is not clearly defined, this may in part be due to an increased risk of respiratory depression when the drugs are used together. The US Food and Drug Administration (FDA) has issued a warning about the co-prescription of opioids and gabapentinoids [<a href="#rid19">19</a>]. No data are available on the joint impact of opioids and gabapentin on breathing during sleep, but it is highly likely that the respiratory depression noted during sleep is even more pronounced in the setting of existing sleep apnea and may even contribute to the development of SDB in those without prior sleep apnea.</p><p>Some overlap with recognized risks factors for OSA does exist. In a study of over 330 patients seen at university-affiliated pain clinics, the two factors independently associated with increased risk of moderate-to-severe SDB were higher scores on the STOP-Bang questionnaire (a screening tool for OSA) and lower daytime oxyhemoglobin saturation (SpO<sub>2</sub>) [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H1326602863"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>The phenotype of sleep-disordered breathing (SDB) associated with chronic opioid use differs from central sleep apnea (CSA) due to other conditions. Abnormalities generally fall under three domains [<a href="#rid13">13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Altered or irregular respiratory patterns, in particular ataxic breathing, also known as Biot's respiration. This pattern is characterized by breaths that are irregular in tidal volume and frequency, interspersed with central pauses  (<a class="graphic graphic_waveform graphicRef106970" href="/z/d/graphic/106970.html" rel="external">waveform 1</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Apneas and hypopneas, which are often predominantly central  (<a class="graphic graphic_waveform graphicRef105895" href="/z/d/graphic/105895.html" rel="external">waveform 2</a>); prolonged obstructive hypopneas may also be seen  (<a class="graphic graphic_waveform graphicRef105897" href="/z/d/graphic/105897.html" rel="external">waveform 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abnormalities in gas exchange (eg, hypoxemia, hypercarbia). </p><p></p><p>In one study of 98 patients with chronic pain, opioids were potentially responsible for hypoxemia (defined as oxygen saturation &lt;90 percent) in 10 percent of patients during wakefulness [<a href="#rid20">20</a>]. Additionally, during sleep, 8 percent of patients exhibited hypoxemia not clearly related to apneas and hypopneas.</p><p>Irregular breathing patterns are particularly common during non-rapid eye movement (NREM) sleep. In one study, ataxic breathing was present in 70 percent of 50 patients on chronic opioid therapy during NREM sleep, including 92 percent of patients taking a daily <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> equivalent dose greater than 200 mg [<a href="#rid14">14</a>].</p><p>Daytime symptoms of SDB are variable and often nonspecific. Patients may have no complaints or they may report daytime sleepiness and fatigue, which may also be attributed to underlying disease, opioid use, or other medications. Nighttime sleep disturbances may be reported by the patient or a bed partner, or not at all.</p><p class="headingAnchor" id="H1326602870"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Sleep-disordered breathing (SDB) among patients who use opioids is primarily a polysomnographic diagnosis, and disease severity is established based on a combination of polysomnogram (PSG) results and clinical symptoms.</p><p class="headingAnchor" id="H1352630880"><span class="h2">Patient selection for polysomnography</span><span class="headingEndMark"> — </span>Diagnosis of SDB in patients chronically using opioids requires a high index of suspicion and PSG, as there are few reliable symptoms during wakefulness, and central apneas or irregular breathing patterns during sleep may not be apparent to the patient or to a bed partner.</p><p>Of the available screening questionnaires for obstructive sleep apnea (OSA), higher scores on the STOP-BANG instrument have been shown, in a predictive model, to be associated with higher odds of SDB in patients who chronically use opioids [<a href="#rid17">17</a>]. However, use of the instrument has not been validated as a selection tool for PSG. Given this, patient selection for PSG is challenging. Adding to the uncertainty is the relative lack of outcome data in patients with opioid-associated SDB. (See  <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">"Clinical presentation and diagnosis of obstructive sleep apnea in adults", section on 'Screening questionnaires'</a>.)</p><p>Until more data are available to guide clinical decision making, we suggest using a combination of clinical symptoms of disturbed sleep (eg, excessive daytime sleepiness, reports of poor sleep quality, frequent arousals from sleep), known risk factors for CSA in patients who chronically use opioids (eg, high daily opioid dose), and high-risk comorbid conditions (eg, heart failure, respiratory disease) to select patients for PSG. In practice, there should be a low threshold to obtain PSG in any patient on chronic opioid therapy who complains of excessive daytime sleepiness or any symptom of disturbed sleep, particularly when the daily <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> dose equivalent is greater than 200 mg, as the pretest probability of SDB in this population is quite high. (See <a class="local">'Prevalence'</a> above and <a class="local">'Risk factors'</a> above.)</p><p>In-laboratory attended PSG is the test of choice in this setting. Use of end-tidal or transcutaneous carbon dioxide monitoring during PSG is required to diagnose sleep-related hypoventilation. Home sleep apnea testing (HSAT) is not advised in cases of suspected opioid-related SDB, since the likelihood of central apneas is high and HSAT cannot reliably distinguish between obstructive and central apneas. (See  <a class="medical medical_review" href="/z/d/html/7701.html" rel="external">"Central sleep apnea: Risk factors, clinical presentation, and diagnosis", section on 'Evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/99553.html" rel="external">"Polysomnography in the evaluation of sleep-disordered breathing in adults", section on 'Ventilation'</a>.)</p><p class="headingAnchor" id="H1352630886"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>The International Classification of Sleep Disorders, third edition (ICSD-3) criteria for diagnosis of CSA due to opioids (or other medications or substances) require all of the following [<a href="#rid21">21</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The patient is taking an opioid or other respiratory depressant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient reports sleepiness, awakening with shortness of breath, snoring, witnessed apneas, or insomnia (difficulty initiating or maintaining sleep, frequent awakenings, or nonrestorative sleep).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PSG reveals ≥5 central apneas and/or central hypopneas per hour of sleep; the number of central apneas and/or central hypopneas is &gt;50 percent of the total number of apneas and hypopneas; and there is no evidence of Cheyne-Stokes breathing. (See  <a class="medical medical_review" href="/z/d/html/99553.html" rel="external">"Polysomnography in the evaluation of sleep-disordered breathing in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The disorder is not better explained by another current sleep disorder.</p><p></p><p>Diagnostic criteria for OSA in patients chronically using opioids are identical to those of the general population. (See  <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">"Clinical presentation and diagnosis of obstructive sleep apnea in adults", section on 'Diagnosis'</a>.) </p><p class="headingAnchor" id="H14082132"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Treatment of opioid-associated sleep-disordered breathing (SDB) involves lowering or eliminating the opioid dose, avoidance of concomitant medications that may worsen hypoxemia during sleep, and positive airway pressure (PAP) therapy in selected patients.</p><p class="headingAnchor" id="H1326602912"><span class="h2">Lowering the opioid dose</span><span class="headingEndMark"> — </span>Most data support a dose-response relationship between opioid daily dose and severity of sleep-disordered breathing (SDB) [<a href="#rid13">13</a>]. Therefore, lowering or eliminating the opioid dose should be considered first-line therapy, when possible. Consideration should be given to alternative non-opioid analgesics and other therapeutic pain control modalities.<strong> </strong>(See  <a class="medical medical_review" href="/z/d/html/126111.html" rel="external">"Approach to the management of chronic non-cancer pain in adults"</a>.)</p><p class="headingAnchor" id="H1352630848"><span class="h2">Concomitant drugs</span><span class="headingEndMark"> — </span>Patients receiving opioids for chronic pain or those in <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> maintenance programs may also use other prescription medications, including benzodiazepines, antidepressants, and gabapentinoid drugs (eg, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>), which can contribute to worsening hypoxemia and hypercarbia during sleep. In the setting of SDB, the doses of these medications should be reduced if possible when prescribed concomitantly with opioids [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H1326602926"><span class="h2">Positive airway pressure therapy</span><span class="headingEndMark"> — </span>There is scant direct evidence upon which to base treatment recommendations regarding PAP therapy for SDB in patients chronically using opioids. It is not entirely clear whether central apneas, in the absence of hypoxemia, have significant and long-term clinical effects in this patient population, and it is not known whether specific treatment of the central apneas will result in positive short- or long-term outcomes.</p><p>Treatment decisions must therefore be individualized based on disease severity, symptom severity, and patient willingness to accept PAP therapy. We typically suggest a trial of PAP therapy in patients with hypoxemia during sleep, those with moderate to severe SDB (apnea-hypopnea index [AHI] &gt;15), and those with mild SDB (AHI 5 to 15) who also report poor sleep quality or nighttime sleep disturbances.</p><p>Although continuous positive airway pressure (CPAP) therapy is an effective first-line therapy for OSA, its effectiveness in the setting of opioid-induced SDB is less encouraging. Several small studies have shown that CPAP therapy eliminates the obstructive events but has minimal effect on ataxic breathing and hypoxemia, and may even worsen the central apnea associated with chronic opioid therapy [<a href="#rid23">23-28</a>]. Other PAP modalities such as rate-controlled bilevel PAP (BPAP) and adaptive servo-ventilation (ASV) may be more effective, but data are limited to small case series, and no trials have compared different modalities in patients with opioid-associated SDB [<a href="#rid25">25,29,30</a>]. </p><p>A 2021 systemic review highlighted the paucity of evidence on the treatment of SDB associated with chronic opioid use but concluded that rate-controlled BPAP or ASV may be more effective than CPAP in normalizing the apnea-hypopnea index (AHI) [<a href="#rid31">31</a>]. None of the studies reported on long-term outcomes such as morbidity and mortality [<a href="#rid31">31</a>]. </p><p>Of note, the SERVE-HF trial found that ASV increased cardiovascular and all-cause mortality in patients with CSA and heart failure with reduced ejection fraction (≤45 percent) [<a href="#rid32">32</a>]. Therefore, ASV should be avoided in the subset of patients with opioid-induced central apnea who have concomitant heart failure and reduced ejection fraction. (See  <a class="medical medical_review" href="/z/d/html/7675.html" rel="external">"Central sleep apnea: Treatment", section on 'Patients with ejection fraction ≤45 percent'</a>.)</p><p>PAP titration and mode selection in patients with opioid-induced SDB should be done in conjunction with an experienced sleep specialist. The particular PAP mode prescribed is best determined during overnight attended (in-laboratory) polysomnography (PSG). Titration is typically started with CPAP and then switched to ASV or BPAP with a back-up rate to eliminate observed respiratory events (apneas and hypopneas) and ensure adequate oxygenation. On occasion, a second night of PAP titration may be necessary. (See  <a class="medical medical_review" href="/z/d/html/105590.html" rel="external">"Mode selection for positive airway pressure titration in adult patients with central sleep apnea syndromes", section on 'Patients with CSA and opioid use'</a>.)</p><p class="headingAnchor" id="H1352630873"><span class="h2">Supplemental oxygen</span><span class="headingEndMark"> — </span>During in-laboratory PSG and titration, some patients have significant sleep-related hypoxemia (eg, baseline oxygen saturation &lt;90 percent) that persists despite PAP therapy, with desaturations that are not clearly associated with apneas and hypopneas. In these patients, supplemental oxygen is typically administered along with PAP therapy in order to maintain oxygen saturation &gt;90 percent during sleep. Oxygen alone (without PAP therapy) is not adequate therapy for opioid-associated SDB.</p><p>The cause of persistent sleep-related hypoxemia in these patients is presumed to be hypoventilation due to the opioids themselves in most cases. Further evaluation may be indicated if there is clinical suspicion for underlying lung or cardiac disease or if hypoxemia is also present during wakefulness.</p><p>The risk of oxygen-induced hypercapnia in patients with opioid-induced SDB is unknown. Noninvasive carbon dioxide monitoring is not routinely performed during PSG in adults but may be used if there is clinical concern for hypoventilation. (See  <a class="medical medical_review" href="/z/d/html/99553.html" rel="external">"Polysomnography in the evaluation of sleep-disordered breathing in adults", section on 'Ventilation'</a>.)</p><p class="headingAnchor" id="H1352630962"><span class="h1">FOLLOW-UP AND MONITORING</span><span class="headingEndMark"> — </span>Patients who are started on positive airway pressure (PAP) therapy should be monitored by the prescribing clinician, typically a sleep physician, within the first few weeks of initiation of therapy and at minimum once more during the first year, then at least yearly thereafter. Adherence to therapy should be objectively documented at each visit.</p><p>Repeat polysomnography (PSG) should be considered if opioid medication dose is increased, if the patient reports new clinical symptoms or sleep disturbance, and/or when PAP machine inquiry suggests residual apnea-hypopnea index (AHI) &gt;5 and suboptimal therapy. (See  <a class="medical medical_review" href="/z/d/html/7695.html" rel="external">"Obstructive sleep apnea: Overview of management in adults", section on 'Follow-up'</a>.)</p><p class="headingAnchor" id="H1647160597"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The long-term effects of sleep-disordered breathing (SDB) in patients who chronically use opioids are not currently known. However, a robust body of literature in the general population indicates that patients with SDB, in particular obstructive sleep apnea (OSA), are at increased risk for a range of adverse outcomes, including impaired daytime function, accidents, cardiovascular morbidity, metabolic dysregulation, and all-cause mortality. </p><p>While more studies are needed, irregular or ataxic breathing has been shown to be a sensitive predictor of impending respiratory depression in adults and children, potentially explaining, at least in part, the increased mortality observed with chronic opioid use [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H3195171088"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113310.html" rel="external">"Society guideline links: Sleep-related breathing disorders in adults"</a>.)</p><p class="headingAnchor" id="H14082138"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Effects of opioids on sleep and breathing</strong> – Chronic opioid therapy is associated with significant alterations and irregularity in breathing during both sleep and wake in many patients. Sleep-disordered breathing (SDB) includes varying combinations of hypoventilation, obstructive and central apneas  (<a class="graphic graphic_waveform graphicRef105895" href="/z/d/graphic/105895.html" rel="external">waveform 2</a>), mixed apneas, and irregular breathing patterns during sleep. (See <a class="local">'Effects of opioids on sleep and respiration'</a> above.)</p><p></p><p class="bulletIndent1">The most common form of SDB associated with chronic opioid use is central sleep apnea (CSA), which is identified in approximately 25 percent of patients. (See <a class="local">'Prevalence'</a> above and <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors for SDB in patients with chronic opioid use</strong> – The two most consistently identified risk factors for SDB in patients who chronically use opioids are low to low-normal body mass index and daily dose of opioid, with a daily <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> dose equivalent &gt;200 mg associated with highest risk. Low SpO<sub>2 </sub>has been associated with obstructive sleep apnea (OSA), and high daily morphine dose equivalent has been associated with CSA. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Diagnosis of SDB requires a high index of suspicion and observed polysomnography (PSG), as there are few reliable symptoms during wakefulness, and central apneas during sleep may not be apparent to the patient or to a bed partner.</p><p></p><p class="bulletIndent1">PSG should be considered in any patient on chronic opioid therapy who complains of excessive daytime sleepiness or any symptom of disturbed sleep, particularly when the daily <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> dose equivalent is greater than 200 mg, as the pretest probability of SDB in this population is quite high. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Medication adjustments</strong> – Lowering or eliminating the opioid dose is the preferred first-line therapy, when possible. Concomitant drugs that may be contributing to SDB, such as benzodiazepines, should also be decreased or discontinued. (See <a class="local">'Lowering the opioid dose'</a> above and <a class="local">'Concomitant drugs'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Positive airway pressure (PAP) therapy</strong> – PAP has been used in the treatment of opioid-induced SDB with varying success, but there are no agreed upon criteria for use of PAP in this setting. We suggest a trial of PAP in patients who have hypoxemia during sleep, moderate to severe SDB (apnea-hypopnea index [AHI] &gt;15), or mild SDB (AHI 5 to 15) with reports of poor sleep quality or nighttime sleep disturbances (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2">The decision to use continuous positive airway pressure (CPAP) versus rate controlled bilevel PAP (BPAP) or adaptive servo-ventilation (ASV) should be individualized at the time of PAP titration. In-laboratory titration is recommended and close clinical follow-up is necessary. (See <a class="local">'Positive airway pressure therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Role of supplemental oxygen</strong> – In addition to PAP therapy, patients with significant hypoxemia during sleep (ie, persistent baseline oxygen saturation &lt;90 percent despite PAP therapy, desaturations not clearly associated with apneas and hypopneas) are generally treated with oxygen to maintain oxygen saturation &gt;90 percent. (See <a class="local">'Supplemental oxygen'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and the American Pain Society. Clin J Pain 1997; 13:6.</a></li><li><a class="nounderline abstract_t">Manchikanti L, Helm S 2nd, Fellows B, et al. Opioid epidemic in the United States. Pain Physician 2012; 15:ES9.</a></li><li><a class="nounderline abstract_t">Rosen IM, Aurora RN, Kirsch DB, et al. Chronic Opioid Therapy and Sleep: An American Academy of Sleep Medicine Position Statement. J Clin Sleep Med 2019; 15:1671.</a></li><li><a class="nounderline abstract_t">Dimsdale JE, Norman D, DeJardin D, Wallace MS. The effect of opioids on sleep architecture. J Clin Sleep Med 2007; 3:33.</a></li><li><a class="nounderline abstract_t">Pressman MR. Factors that predispose, prime and precipitate NREM parasomnias in adults: clinical and forensic implications. Sleep Med Rev 2007; 11:5.</a></li><li><a class="nounderline abstract_t">Yue HJ, Guilleminault C. Opioid medication and sleep-disordered breathing. Med Clin North Am 2010; 94:435.</a></li><li><a class="nounderline abstract_t">Tangel DJ, Mezzanotte WS, White DP. Influence of sleep on tensor palatini EMG and upper airway resistance in normal men. J Appl Physiol (1985) 1991; 70:2574.</a></li><li><a class="nounderline abstract_t">Pattinson KT. Opioids and the control of respiration. Br J Anaesth 2008; 100:747.</a></li><li><a class="nounderline abstract_t">Teichtahl H, Wang D, Cunnington D, et al. Ventilatory responses to hypoxia and hypercapnia in stable methadone maintenance treatment patients. Chest 2005; 128:1339.</a></li><li><a class="nounderline abstract_t">Martins RT, Carberry JC, Wang D, et al. Morphine alters respiratory control but not other key obstructive sleep apnoea phenotypes: a randomised trial. Eur Respir J 2020; 55.</a></li><li><a class="nounderline abstract_t">Teichtahl H, Prodromidis A, Miller B, et al. Sleep-disordered breathing in stable methadone programme patients: a pilot study. Addiction 2001; 96:395.</a></li><li><a class="nounderline abstract_t">Farney RJ, McDonald AM, Boyle KM, et al. Sleep disordered breathing in patients receiving therapy with buprenorphine/naloxone. Eur Respir J 2013; 42:394.</a></li><li><a class="nounderline abstract_t">Correa D, Farney RJ, Chung F, et al. Chronic opioid use and central sleep apnea: a review of the prevalence, mechanisms, and perioperative considerations. Anesth Analg 2015; 120:1273.</a></li><li><a class="nounderline abstract_t">Walker JM, Farney RJ, Rhondeau SM, et al. Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing. J Clin Sleep Med 2007; 3:455.</a></li><li><a class="nounderline abstract_t">Wang D, Teichtahl H, Drummer O, et al. Central sleep apnea in stable methadone maintenance treatment patients. Chest 2005; 128:1348.</a></li><li><a class="nounderline abstract_t">Walker JM, Farney RJ. Are opioids associated with sleep apnea? A review of the evidence. Curr Pain Headache Rep 2009; 13:120.</a></li><li><a class="nounderline abstract_t">Chung F, Wong J, Bellingham G, et al. Predictive factors for sleep apnoea in patients on opioids for chronic pain. BMJ Open Respir Res 2019; 6:e000523.</a></li><li><a class="nounderline abstract_t">Gomes T, Juurlink DN, Antoniou T, et al. Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study. PLoS Med 2017; 14:e1002396.</a></li><li class="breakAll">FDA In Brief: FDA requires new warnings for gabapentinoids about risk of respiratory depression. US Food and Drug Administration (FDA), December 19, 2019. Available at: https://www.fda.gov/news-events/fda-brief/fda-brief-fda-requires-new-warnings-gabapentinoids-about-risk-respiratory-depression, accessed Jan 14, 2020. https://www.fda.gov/news-events/fda-brief/fda-brief-fda-requires-new-warnings-gabapentinoids-about-risk-respiratory-depression (Accessed on January 14, 2020).</li><li><a class="nounderline abstract_t">Mogri M, Desai H, Webster L, et al. Hypoxemia in patients on chronic opiate therapy with and without sleep apnea. Sleep Breath 2009; 13:49.</a></li><li class="breakAll">American Academy of Sleep Medicine. International Classification of Sleep Disorders, 3rd ed, American Academy of Sleep Medicine, 2014.</li><li><a class="nounderline abstract_t">Mason M, Cates CJ, Smith I. Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea. Cochrane Database Syst Rev 2015; :CD011090.</a></li><li><a class="nounderline abstract_t">Farney RJ, Walker JM, Boyle KM, et al. Adaptive servoventilation (ASV) in patients with sleep disordered breathing associated with chronic opioid medications for non-malignant pain. J Clin Sleep Med 2008; 4:311.</a></li><li><a class="nounderline abstract_t">Guilleminault C, Cao M, Yue HJ, Chawla P. Obstructive sleep apnea and chronic opioid use. Lung 2010; 188:459.</a></li><li><a class="nounderline abstract_t">Javaheri S, Harris N, Howard J, Chung E. Adaptive servoventilation for treatment of opioid-associated central sleep apnea. J Clin Sleep Med 2014; 10:637.</a></li><li><a class="nounderline abstract_t">Javaheri S, Malik A, Smith J, Chung E. Adaptive pressure support servoventilation: a novel treatment for sleep apnea associated with use of opioids. J Clin Sleep Med 2008; 4:305.</a></li><li><a class="nounderline abstract_t">Ramar K, Ramar P, Morgenthaler TI. Adaptive servoventilation in patients with central or complex sleep apnea related to chronic opioid use and congestive heart failure. J Clin Sleep Med 2012; 8:569.</a></li><li><a class="nounderline abstract_t">Troitino A, Labedi N, Kufel T, El-Solh AA. Positive airway pressure therapy in patients with opioid-related central sleep apnea. Sleep Breath 2014; 18:367.</a></li><li><a class="nounderline abstract_t">Reddy R, Adamo D, Kufel T, et al. Treatment of opioid-related central sleep apnea with positive airway pressure: a systematic review. J Opioid Manag 2014; 10:57.</a></li><li><a class="nounderline abstract_t">Shapiro CM, Chung SA, Wylie PE, et al. Home-use servo-ventilation therapy in chronic pain patients with central sleep apnea: initial and 3-month follow-up. Sleep Breath 2015; 19:1285.</a></li><li><a class="nounderline abstract_t">Ahmad A, Ahmad R, Meteb M, et al. The relationship between opioid use and obstructive sleep apnea: A systematic review and meta-analysis. Sleep Med Rev 2021; 58:101441.</a></li><li><a class="nounderline abstract_t">Cowie MR, Woehrle H, Wegscheider K, et al. Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure. N Engl J Med 2015; 373:1095.</a></li><li><a class="nounderline abstract_t">Bouillon T, Bruhn J, Roepcke H, Hoeft A. Opioid-induced respiratory depression is associated with increased tidal volume variability. Eur J Anaesthesiol 2003; 20:127.</a></li></ol></div><div id="topicVersionRevision">Topic 97859 Version 8.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9084947" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and the American Pain Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22786464" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Opioid epidemic in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31739858" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Chronic Opioid Therapy and Sleep: An American Academy of Sleep Medicine Position Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17557450" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The effect of opioids on sleep architecture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17208473" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Factors that predispose, prime and precipitate NREM parasomnias in adults: clinical and forensic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20451025" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Opioid medication and sleep-disordered breathing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1885452" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Influence of sleep on tensor palatini EMG and upper airway resistance in normal men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18456641" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Opioids and the control of respiration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16162727" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Ventilatory responses to hypoxia and hypercapnia in stable methadone maintenance treatment patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32165399" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Morphine alters respiratory control but not other key obstructive sleep apnoea phenotypes: a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11255580" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Sleep-disordered breathing in stable methadone programme patients: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23100497" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Sleep disordered breathing in patients receiving therapy with buprenorphine/naloxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25988636" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Chronic opioid use and central sleep apnea: a review of the prevalence, mechanisms, and perioperative considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17803007" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16162728" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Central sleep apnea in stable methadone maintenance treatment patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19272277" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Are opioids associated with sleep apnea? A review of the evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31908788" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Predictive factors for sleep apnoea in patients on opioids for chronic pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28972983" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28972983" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18683000" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Hypoxemia in patients on chronic opiate therapy with and without sleep apnea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18683000" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Hypoxemia in patients on chronic opiate therapy with and without sleep apnea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26171909" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18763421" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Adaptive servoventilation (ASV) in patients with sleep disordered breathing associated with chronic opioid medications for non-malignant pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20658143" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Obstructive sleep apnea and chronic opioid use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24932143" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Adaptive servoventilation for treatment of opioid-associated central sleep apnea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18763420" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Adaptive pressure support servoventilation: a novel treatment for sleep apnea associated with use of opioids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23066370" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Adaptive servoventilation in patients with central or complex sleep apnea related to chronic opioid use and congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24062011" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Positive airway pressure therapy in patients with opioid-related central sleep apnea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24604570" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Treatment of opioid-related central sleep apnea with positive airway pressure: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25813356" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Home-use servo-ventilation therapy in chronic pain patients with central sleep apnea: initial and 3-month follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33567395" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The relationship between opioid use and obstructive sleep apnea: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26323938" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12622497" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Opioid-induced respiratory depression is associated with increased tidal volume variability.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
